Site search2017
- 2017.11.17IRPatent Issued in Japan on Method for Reconstructing Immune Function Using Pluripotent Stem Cells（176KB）
- 2017.11.10IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（935KB）
- 2017.10.27NewsCollaborative Research on Fully-personalized Cancer Neoantigen Vaccine（583KB）
- 2017.10.3NewsAnnouncement on the Start of Joint Research with Juntendo University（610KB）
- 2017.8.14IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（805KB）
- 2017.7.24IRPatent for rejuvenated antigen-specific T lymphocytes using iPS cells（367KB）
- 2017.7.20IRDecision to grant patent for CTL inducer composition by Canadian Intellectual Property Office（633KB）
- 2017.7.1NewsWe changed the company name from "GreenPeptide Co., Ltd." to " BrightPath Biotherapeutics Co., Ltd.
- 2017.6.14PRGreenPeptide will exhibit in the Japan Pavilion (Booth #1911) of 2017 BIO International Convention, the world's largest business matching event in San Diego (USA) from June20 to 22.
- 2017.5.15IRDecision to Grant a Patent Related to Antigenic Peptides Derived from the T790M Point Mutation of Epidermal Growth Factor Receptor（93 KB）
- 2017.5.12IRAnnouncement on the Issuance of Stock Options (Subscription Rights to Shares)（102KB）
- 2017.5.12IRAnnouncement on the Change of the Corporate Name and Partial Amendment to the Articles of Incorporation（66 KB）
- 2017.5.12IRAnnouncement Concerning Differences between Consolidated Financial Forecast and Results（66KB）
- 2017.5.12IRFinancial Results for the Fiscal Year ended March 31, 2017 [Japanese GAAP] (Consolidated)（171KB）
- 2017.2.10IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (Consolidated)（183KB）
- 2017.1.27IRNotice of the initiation of a phase II clinical trial of GRN-1201 with the concomitant use of an immune checkpoint antibody against NSCLC in the U.S.（90KB）
- 2017.11.17IRPatent Issued in Japan on Method for Reconstructing Immune Function Using Pluripotent Stem Cells（176KB）
- 2017.11.10IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（935KB）
- 2017.8.14IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（805KB）
- 2017.7.24IRPatent for rejuvenated antigen-specific T lymphocytes using iPS cells（367KB）
- 2017.7.20IRDecision to grant patent for CTL inducer composition by Canadian Intellectual Property Office（633KB）
- 2017.5.15IRDecision to Grant a Patent Related to Antigenic Peptides Derived from the T790M Point Mutation of Epidermal Growth Factor Receptor（93 KB）
- 2017.5.12IRAnnouncement on the Issuance of Stock Options (Subscription Rights to Shares)（102KB）
- 2017.5.12IRAnnouncement on the Change of the Corporate Name and Partial Amendment to the Articles of Incorporation（66 KB）
- 2017.5.12IRAnnouncement Concerning Differences between Consolidated Financial Forecast and Results（66KB）
- 2017.5.12IRFinancial Results for the Fiscal Year ended March 31, 2017 [Japanese GAAP] (Consolidated)（171KB）
- 2017.2.10IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (Consolidated)（183KB）
- 2017.1.27IRNotice of the initiation of a phase II clinical trial of GRN-1201 with the concomitant use of an immune checkpoint antibody against NSCLC in the U.S.（90KB）